| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0028-3908(94)00153-J |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:002839089400153J?httpAccept=text/xml |
| https://api.elsevier.com/content/article/PII:002839089400153J?httpAccept=text/plain | ||
| P698 | PubMed publication ID | 7630480 |
| P2093 | author name string | J. Williams | |
| R. G. Hill | |||
| D. J. Williamson | |||
| R. J. Hargreaves | |||
| S. L. Shepheard | |||
| P2860 | cites work | Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994 | Q72071728 |
| Vasoactive peptide release in the extracerebral circulation of humans during migraine headache | Q28265001 | ||
| CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges | Q28326822 | ||
| Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine | Q35234469 | ||
| The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater | Q35887963 | ||
| Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption | Q36329540 | ||
| Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. | Q37334431 | ||
| Opiate analgesics inhibit substance P release from rat trigeminal nucleus | Q39156657 | ||
| The non‐peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats | Q41957034 | ||
| Timing and topography of cerebral blood flow, aura, and headache during migraine attacks | Q43706641 | ||
| Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow | Q48413486 | ||
| Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space | Q48448907 | ||
| Jun B, c-jun, jun D and c-fos mRNAs in nucleus caudalis neurons: rapid selective enhancement by afferent stimulation | Q48668435 | ||
| Distribution of substance P-responsive and nociceptive neurones in relation to substance P-immunoreactivity within the caudal trigeminal nucleus of the rat | Q48758108 | ||
| Sensory responses of caudal trigeminal neurons to thermal and mechanical stimuli and their behavioural correlates in the rat. | Q51742950 | ||
| Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan | Q57025159 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | NK1 receptor antagonists | Q12744608 |
| P304 | page(s) | 255-261 | |
| P577 | publication date | 1995-03-01 | |
| P1433 | published in | Neuropharmacology | Q15332439 |
| P1476 | title | Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats | |
| P478 | volume | 34 |
| Q43691631 | 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase |
| Q37739587 | 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks? |
| Q32041979 | A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation |
| Q33842943 | Acute and chronic craniofacial pain: brainstem mechanisms of nociceptive transmission and neuroplasticity, and their clinical correlates |
| Q28379537 | Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines |
| Q44073647 | An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. |
| Q52586592 | An update and systematic review on drug therapies for the treatment of refractory chronic cough. |
| Q38162801 | Animal migraine models for drug development: status and future perspectives |
| Q92977121 | Animal models of migraine and experimental techniques used to examine trigeminal sensory processing |
| Q46174319 | Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig |
| Q77164374 | BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential |
| Q48222004 | Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis |
| Q36912182 | Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. |
| Q35569299 | Contemporary concepts of migraine pathogenesis |
| Q35208450 | Convergence of cervical and trigeminal sensory afferents |
| Q60711535 | Current and emerging therapies for migraine prevention and treatment |
| Q48547468 | Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs |
| Q51544635 | Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. |
| Q48715691 | Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. |
| Q36260908 | Does sumatriptan cross the blood-brain barrier in animals and man? |
| Q42572987 | Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist |
| Q52929006 | Effect of hyperoxia on neurogenic plasma protein extravasation in the rat dura mater. |
| Q48148679 | Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis |
| Q44700406 | Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain |
| Q73098697 | Effects of alniditan on neurogenic oedema in the rat dura mater and on contraction of rat basilar artery |
| Q46955605 | Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat. |
| Q36881119 | Effects of the 5-HT1 receptor agonists, sumatriptan and CP 93,129, on dural arterial flow in the rat. |
| Q36474260 | Experimental migraine models and their relevance in migraine therapy. |
| Q48125110 | Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. |
| Q43574646 | Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model |
| Q48705594 | In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists |
| Q42552312 | Increase of capsaicin-induced trigeminal Fos-like immunoreactivity by 5-HT(7) receptors |
| Q35026810 | Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors |
| Q42127374 | Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine |
| Q48691801 | Is a central action of acute antimigraine drugs essential? |
| Q34412377 | L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays |
| Q42145167 | Melatonin treatment decreases c-fos expression in a headache model induced by capsaicin. |
| Q78019807 | Messenger molecules and receptor mRNA in the human trigeminal ganglion |
| Q34407137 | Modelling headache and migraine and its pharmacological manipulation |
| Q33774490 | Neural mechanisms and pathways in craniofacial pain. |
| Q34272170 | Neuronal messengers in the human cerebral circulation. |
| Q43969540 | Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. |
| Q43607838 | Neuroplasticity induced by tooth pulp stimulation in trigeminal subnucleus oralis involves NMDA receptor mechanisms |
| Q34792793 | New insights into the molecular actions of serotonergic antimigraine drugs. |
| Q36787453 | New migraine and pain research |
| Q44673834 | Passive smoke effects on cough and airways in young guinea pigs: role of brainstem substance P. |
| Q34720188 | Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception |
| Q43964370 | Persistence of attacks of cluster headache after trigeminal nerve root section |
| Q33709238 | Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy |
| Q84979022 | Pharmacology |
| Q28262693 | Potential therapeutic targets for neurokinin-1 receptor antagonists |
| Q34481166 | Preclinical neuropharmacology of naratriptan. |
| Q40532425 | Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan |
| Q48181825 | Prolonged migraine aura without headache arrested by sumatriptan. A case report with further considerations |
| Q43187841 | Release of immunoreactive substance P in the brain stem upon stimulation of the cranial dura mater with low pH - inhibition by the serotonin (5-HT1) receptor agonist CP 93,129. |
| Q48825363 | Release of immunoreactive substance P in the trigeminal brain stem nuclear complex evoked by chemical stimulation of the nasal mucosa and the dura mater encephali--a study with antibody microprobes |
| Q36403060 | Response properties of dural nociceptors in relation to headache |
| Q48685056 | Rizatriptan has central antinociceptive effects against durally evoked responses |
| Q28343904 | Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats |
| Q48538027 | Selective blockade of substance P or neurokinin A receptors reduces the expression of c-fos in trigeminal subnucleus caudalis after corneal stimulation in the rat. |
| Q48289121 | Serotonin in migraine: theories, animal models and emerging therapies. |
| Q47965497 | Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1B/1D receptor: a central action in migraine? |
| Q47734282 | Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation |
| Q74529110 | Substance P receptor (neurokinin-1)-expressing neurons in lamina I of the spinal cord encode for the intensity of noxious stimulation: a c-Fos study in rat |
| Q36869003 | Sumatriptan Inhibits Neurogenic Vasodilation of Dural Blood Vessels in the Anaesthetized Rat—Intravital Microscope Studies |
| Q27349281 | Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice |
| Q73205405 | The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system |
| Q48738077 | The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study |
| Q43685853 | The effect of adrenergic compounds on neurogenic dural vasodilatation |
| Q46980234 | The effects of ibuprofen and the neurokinin-1 receptor antagonist GR205171A on Fos expression in the ferret trigeminal nucleus following tooth pulp stimulation |
| Q34663175 | The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs |
| Q48685051 | The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation |
| Q42706973 | The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist |
| Q33952000 | The pharmacology of headache |
| Q48559123 | The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine |
| Q77619979 | The substance P receptor antagonist CP-99,994 reduces acute postoperative pain |
| Q41757345 | The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles |
| Q52931060 | The use of radiolabelled human serum albumin and SPECT/MRI co-registration to study inflammation in the cavernous sinus of cluster headache patients. |
| Q34555809 | Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain |
| Q42116885 | Trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation |
| Q39129831 | Trigeminal nervous system sensitization by infraorbital nerve injury enhances responses in a migraine model |
| Q48203873 | Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors |
| Q34127399 | Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy |
| Q35748273 | Where do triptans act in the treatment of migraine? |
| Q30890357 | alpha-eudesmol, a P/Q-type Ca(2+) channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion |
Search more.